/ JPH - Citations for Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods Analysis

Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Monday, March 11, 2019 at 4:00 PM to 4:30 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 05.01.18 in Vol 4, No 1 (2018): Jan-Mar

This paper is in the following e-collection/theme issue:

Works citing "Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods Analysis"

According to Crossref, the following articles are citing this article (DOI 10.2196/publichealth.7823):

(note that this is only a small subset of citations)

  1. Mazhar H, Foster BC, Necyk C, Gardiner PM, Harris CS, Robaey P. Natural Health Product–Drug Interaction Causality Assessment in Pediatric Adverse Event Reports Associated with Attention-Deficit/Hyperactivity Disorder Medication. Journal of Child and Adolescent Psychopharmacology 2020;30(1):38
    CrossRef
  2. Geller AI, Zhou EH, Budnitz DS, Lovegrove MC, Dal Pan GJ. Changes in emergency department visits for zolpidem‐attributed adverse drug reactions after FDA Drug Safety Communications. Pharmacoepidemiology and Drug Safety 2020;
    CrossRef
  3. Sendler DJ, Lew-Starowicz M. Digital Ethnography of Zoophilia — A Multinational Mixed-Methods Study. Journal of Sex & Marital Therapy 2019;45(1):1
    CrossRef
  4. Pappa D, Stergioulas LK. Harnessing social media data for pharmacovigilance: a review of current state of the art, challenges and future directions. International Journal of Data Science and Analytics 2019;8(2):113
    CrossRef
  5. Kesselheim AS, Sinha MS, Campbell EG, Schneeweiss S, Rausch P, Lappin BM, Zhou EH, Avorn J, Dal Pan GJ. Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem. Drug Safety 2019;42(11):1287
    CrossRef
  6. Lim SY, Bolster MB. Challenges in Optimizing Medical Education for Rheumatologists. Rheumatic Disease Clinics of North America 2019;45(1):127
    CrossRef
  7. Kesselheim AS, Sinha MS, Rausch P, Lu Z, Tessema FA, Lappin BM, Zhou EH, Dal Pan GJ, Zwanziger L, Ramanadham A, Loughlin A, Enger C, Avorn J, Campbell EG. Patients' Knowledge of Key Messaging in Drug Safety Communications for Zolpidem and Eszopiclone: A National Survey. The Journal of Law, Medicine & Ethics 2019;47(3):430
    CrossRef
  8. Gachloo M, Wang Y, Xia J. A review of drug knowledge discovery using BioNLP and tensor or matrix decomposition. Genomics & Informatics 2019;17(2):e18
    CrossRef
  9. Borchert JS, Wang B, Ramzanali M, Stein AB, Malaiyandi LM, Dineley KE. Adverse Events Due to Insomnia Drugs Reported in a Regulatory Database and Online Patient Reviews: Comparative Study. Journal of Medical Internet Research 2019;21(11):e13371
    CrossRef
  10. . Impact of social media on the US FDA alerts for zolpidem. Reactions Weekly 2018;1685(1):6
    CrossRef